Sign in
RYZB Stock Price, Chart, Stats & News
RayzeBio, Inc. Common Stock
Save
3.75B
Market cap
–
Current P/E
–
Forward P/E
RYZB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -21.12% |
ROE | 82.72% |
D/E | -0.09x |
Interest coverage ratio | – |
RYZB valuation
P/E | – |
P/S | – |
P/B | -22.02x |
P/CF | -47.42x |
P/FCF | -61.70x |
P/OCF | -47.42x |
PEG | -0.36x |
EV multiple | -54.81x |
About
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC).
Similar securities
Based on sector and market capitalization
Report issue